PDF
ePub
Citation
Print
Abstract
Metastatic breast cancer remains incurable. Goals of therapy include tumor shrinkage, symptom control, delay of disease progression and prolongation of survival while maintaining an acceptable quality of life. In case of hormone receptor positive status, non visceral and slowly progressing disease, endocrine therapy is the treatment of choice. Several endocrine agents are currently available including selective estrogen receptor (ER) modulators (tamoxifen), aromatase inhibitors (anastrozole, letrozole and examestane) as well as the selective ER down-regulator, fulvestrant. Chemotherapy has to be preferred in case of hormone receptor negative or rapidly progressive visceral disease regardless of hormone receptor status. Effective agents include taxanes, anthracyclines, vinorelbine, capecitabine, gemcitabine. Combi nation regimens generally result in higher response rates and prolonged time to progression compared with sequential single agents; unfortunately, survival is rarely prolonged and toxicity is higher. This approach should be recommended in young patients with good performance status and visceral disease. Single agents have a better tolerability profile and should be the treatment of choice when a balance between activity and tolerability is needed. In case of HER-2 positive tumors, chemotherapy plus trastuzumab is significantly superior to chemotherapy alone both in terms of response rate and survival and is currently the treatment of choice for these patients. Other target-specific agents targeting the HER- family and vascular endothelial growth factor are currently under investigation.
References
1. Ferlay J. International Agency for Research on Cancer. GLOBOCAN 2000 : cancer incidence, mortality and prevalence worldwide (monograph on CD-ROM). Version 1.0. 2001. Lyon: IARC Press.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer Statistics, 2001. CA Cancer J Clin. 2001. 51:15–36.
3. American Cancer Society. Cancer Facts and Figures 2005. 2005. Atlanta, GA: American Cancer Society;9–11.
4. Chia SKL, Speers C, Kang A. The impact of new chemotherapeutic and hormonal agents on the survival of women with metastatic breast cancer (MBC) in a population based cohort. 2002. In : ASCO Annual Meeting; 20S. abstract # 22.
5. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004. 22:3302–3308.
6. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004. 100:44–52.
7. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998. 16:3439–3460.
8. Ghersi D, Wilcken N, Simes J, Donoghue E. Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2005. 18:CD003366.
9. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996. 14:2197–2205.
10. Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001. 19:343–353.
11. Budzar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol. 1996. 14:2000–2011.
12. Budzar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer. 1998. 83:1142–1152.
13. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998. 16:453–461.
14. Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, et al. Letrozole, a new oral aromatase inhibitor: randomized trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol. 1998. 9:639–645.
15. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, et al. Examestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Examestane Study Group. J Clin Oncol. 2000. 18:1399–1411.
16. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al. Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000. 18:3758–3767.
17. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001. 92:2247–2258.
18. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003. 21:2101–2109.
19. Paridaens R, Therasse P, Dirix L, Beex L, Piccart M, Cameron D, et al. First-line hormonal treatment (HT) for metastatic breast cancer (MBC) with examestane (E) or tamoxifen (T) in postmenopausal patinets (pts) - a randomized phase III trial of EORTC Breast Group. 2004. In : ASCO Annual Meeting; 22S. abstract #515.
20. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, et al. Double-blind randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002. 20:3386–3395.
21. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004. 22:1605–1613.
22. Vergote I, Robertson JF, Kleeberg U, Burton G, Osborne CK, Mauriac L, et al. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat. 2003. 79:207–211.
23. Thurlimann B, Robertson JF, Nabholtz JM, Buzdar A, Bonneterre J. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer. 2003. 39:2310–2317.
24. Forward DP, Cheung KL, Jackson L, Robertson JF. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer. 2004. 90:590–594.
25. Nicholson RI, McClelland RA, Robertson JF, Gee JM. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer. 1999. 6:373–387.
26. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001. 12:1527–1532.
27. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001. 19:3808–3816.
28. Yancik R, Wesley M, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years older. JAMA. 2001. 285:885–892.
29. Conte PF, Gennari A, Donati S, Salvadori B, Baldini E, Bengala C, et al. Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study. Breast Cancer Res Treat. 2001. 68:171–179.
30. Cappuzzo F, Mazzoni F, Gennari A, Donati S, Salvadori B, Orlandini C, et al. Multicentric phase II trial of gemcitabine plus epirubicin and paclitaxel as first-line chemotherapy in metastatic breast cancer. Br J Cancer. 2004. 90:31–35.
31. Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol. 2001. 19:1707–1715.
32. Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, et al. Doxorubicin and palcitaxel versus doxorubicin and cyclphosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol. 2002. 20:3114–3121.
33. Nabholtz JM, Falkson C, Campos D, Szanto J, Martin M, Chan S, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as firs-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter phase III trial. J Clin Oncol. 2003. 21:968–975.
34. Mackey JR, Paterson A, Dirix L, Dewar J, Chap L, Martin M, et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). 2002. In : ASCO Annual Meeing; 20S. abstract #137.
35. Bontembal M, Braun JJ, Creemers JG. Phase III study comparing AT (adryamicin, docetaxel) to FAC (fluorouracil, adriamicin, cyclophosphamide) as first-line chemotherapy (CT) in patients with metastatic breast cancer (MBC). 2003. In : 8th Nottingham International Breast Cancer Conference; 1. abstract # 201.[h2].
36. Gennari A, Bruzzi P, Orlandini C, Salvadori B, Donati S, Landucci E, et al. Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy. Br J Cancer. 2004. 90:962–967.
37. Gennari A, Salvadori B, Donati S, Bengala C, Orlandini C, Danesi R, et al. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol. 1999. 17:3596–3602.
38. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004. 15:440–449.
39. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001. 9:4216–4223.
40. Seidman AD, Berry D, Cirrincione C, Harris L, Dressler L, Muss H, et al. CALGB 9840: phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every thrid week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. 2004. In : ASCO Annual Meeting; 22S. abstract #512.
41. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, et al. Multicenter phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001. 92:1759–1768.
42. Reichardt P, von Minckwitz G, Luck HJ, Thuss-Patience PC, Jonat W, Kolbl H, et al. Capecitabine: the new standard in metastatic breast cancer failing anthracycline and taxane containing chemotherapy? Mature results of a large multicenter phase II trial. Eur J Cancer. 2001. 37:suppl 6. S191.
43. Zelek L, Barthier S, Riofrio M, Fizazi K, Rixe O, Delord JP, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer. 2001. 92:2267–2272.
44. Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 2003. 21:35–40.
45. Miles D, von Minckwitz G, Seidman AD. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist. 2002. 7:13–19.
46. Ocana A, Hortobagyi GN, Esteva FJ. Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer. Clin Breast Cancer. 2006. 6:495–504.
47. O'haughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, et al. Superior survival with capecitabine plus docetaxel combination therapy in antracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002. 20:2812–2823.
48. Albain KS, Nag S, Calderillo-Ruiz G, Jordaan JP, Llombart A, Pluzanska A, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. 2004. In : ASCO Annual Meeting; 22S. abstract #510.
49. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, et al. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel, as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol. 2003. 21:588–592.
50. Conte PF, Guarneri V, Bruzzi P, Prochilo T, Salvadori B, Bolognesi A, et al. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer. 2004. 101:704–712.
51. Alba E, Martin M, Ramos M, Adrover E, Balil A, Jara C, et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol. 2004. 22:2587–2593.
52. Tait CR, Waterworth A, Loncaster J, Horgan K, Dodwell D. The oligometastatic state in breast cancer: hypothesis or reality. Breast. 2005. 14:87–93.
53. Stockler M, Wilcken N, Coates A. Chemotherapy for metastatic breast cancer -when is enough enough? Eur J Cancer. 1997. 33:2147–2148.
54. Gennari A, Conte P, Nanni O, Manzione L, Cortesi E, Boni C, et al. Multicenter randomized trial of paclitaxel (P) maintenance chemotherapy (CT) versus control in metastatic breast cancer (MBC) patients achieving a response or stable disease to first-line CT including anthracyclines and paclitaxel: final results from the Italian MANTA study. 2005. In : ASCO Annual Meeting; 23S. abstract #522.
55. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst. 2004. 96:739–749.
56. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med. 2001. 344:783–792.
57. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002. 20:1215–1221.
58. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administrated as first-line treatment: the M77001 study group. J Clin Oncol. 2005. 23:4265–4274.
59. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, et al. Trastuzumab and vinorelbine as first-line therapy for HER-2 overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors and cardiac surveillance algorithm. J Clin Oncol. 2003. 21:2889–2895.
60. Konecny GE, Pegram MD. Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression. Oncology. 2004. 18:S32–S36.
61. Robert N, Leyland-Jones B, Asmar L. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with Her2/neu positive advanced breast cancer. Breast Cancer Res Treat. 2002. 76:suppl 1. S37. [h3].
62. Burris HA III. Dual kinase inhibition in the treatment of breast cancer: initial experience with EGFR/ErbB2 inhibitor lapatinib. Oncologist. 2004. 9:10–15.
63. Storniolo AM, Burris H, Pegram M, Overmoyer B, Miller K, Jones S, et al. A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen. 2005. In : ASCO Annual Meeting; 23S. abstract #559.
64. Gomez HL, Chavez MA, Doval DC, Chow LWC, Wood BA, Berger MS, et al. A phase II randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as first-line treatment in patients with FISH positive advanced or metastatic breast cancer. 2005. In : ASCO Annual Meeting; 23S. abstract #3046.
65. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005. 23:792–799.
66. Miller KD, Wang M, Gralow J. E2100 a randomized phaseIII trial of psclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. 2004. In : Presented at 2004 ASCO Annual Meeting; [h4].
67. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996. 14:2552–2559.
68. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003. 98:1735–1744.
XML Download